The Aragonese mask with 'nanosilver' arouses interest in manufacturers
2 March, 2021
The families of Izas, Franck, Anna, Mathys and Nina fund research into a rare childhood cancer
3 March, 2021
Although last December a candidate from the Belgian pharmaceutical company Janssen entered the final phase of clinical trials, the Human Immunodeficiency Virus (HIV) - which if untreated causes AIDS - has seen a decade pass without a successful attempt to achieve a medicine that prevents chronic infection of the human body
The unprecedented speed with which anticovid vaccines have been developed has once again put a question on the table: why do other viruses with global impact such as HIV still not have effective antivirals?
Although last December a candidate from the Belgian pharmaceutical company Janssen entered the final phase (III) of clinical trials, the Human Immunodeficiency Virus (HIV) - which if untreated causes AIDS - has already seen a decade pass without a successful attempt to achieve a medicine that prevents its chronic infection of the human body.
Meanwhile, and while 38 million people in the world are infected by this virus, another pathogen, SARS-CoV-2, has managed in just a year and a half for the pharmaceutical industry to develop functional vaccines that successfully stimulate a response. immunity and that have even revolutionized biotechnology.
In this race they have won the urgency of containing a massive contagion, the previous experience with epidemics of other coronaviruses and the urgent need for medicines to contain covid-19.
Precisely, this very disparate situation has plagued social networks with questions about what the differences are between both diseases, why one has been in development for decades and the other appeared so quickly, and whether there are hidden interests that obstruct a vaccine against AIDS and have slowed its development. financing.
